[S24] Research frontiers on viral infection and antiviral therapy: Cross-sectional approach toward drug discovery and development

Sun. Mar 28, 2021 1:15 PM - 3:15 PM [Room H] Oral Presentation H (Online)

Organizer: Iwatani Yasumasa (NHO Nagoya Med. Ctr.), Misumi Shogo (Global Ctr. Natural Resources Sci., Kumamoto Univ.), Tamamura Hirokazu (Inst. Biomat. Bioeng., Tokyo Med. Dent. Univ.)

The rapid global spread of Covid-19 (Coronavirus disease-2019) threatens us in Japan as well as people in the world. The causative pathogen is a new class of coronavirus, known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2). In early 2020, we faced difficulties in diagnostic detection, clinical management and drug therapy for Covid-19. In these situations, various cross-disciplinary information of basic science is needed, especially to develop new therapeutic drugs and vaccines through drug repositioning. Therefore, now is the perfect time to revisit cross-sectional studies on antiviral mechanisms that are common in different virus species. Last year, the “antiviral research frontier” group planned a symposium based on this concept, although the actual lectures were unfortunately canceled. Therefore, we rearranged this session that consists of two major topics: antiviral metal-chelating inhibitors and therapeutic drugs/vaccines against SARS-CoV-2. We hope that the session helps many scientists to discuss widely across different virus species as well as to further develop novel antiviral drugs through cross-disciplinary studies of antiviral mechanisms.

+Add all to schedule

趣旨説明：岩谷靖雅^1,2（1. 国立病院名古屋医療セ臨床研セ，2. 名大院医） (1:15 PM - 1:20 PM)

1:20 PM - 1:42 PM

[S24-1] Development of the inhibitors for HIV-1 reverse transcriptase RNase H activity

○Tyuji Hoshino¹ (1. Grad. Schl. Pharm. Sci., Chiba Univ.)

1:42 PM - 2:04 PM

[S24-2] Discovery of cap-dependent endonuclease inhibitor, baloxavir marboxil

○Takeshi Noshi¹ (1. Shionogi & Co., Ltd.)

2:04 PM - 2:26 PM

[S24-3] Development of coronavirus 3CL protease inhibitor for the treatment of COVID-19

○Yoshio Hayashi¹, Sho Konno¹, Kiyotaka Kobayashi¹, Wataru Kamitani², Toshiya Senda³, Miki Senda³, Masaki Kojima⁴, Yoshiyuki Shirasaka⁵ (1. Tokyo Univ. of Pharm. and Life Sci., 2. Gunma Univ. Graduate School of Medicine, 3. IMSS, KEK, 4. Tokyo Univ. of Pharm. and Life Sci. , 5. Kanazawa Univ. Faculty of Pharm. Sci.)

2:26 PM - 2:48 PM

[S24-4] Development of COVID-19 vaccine in Japan using self-amplifying RNA technology

○Wataru Akahata¹ (1. VLP Therapeutics Japan, LLC)

2:48 PM - 3:10 PM

[S24-5] Development of antibody mimetics against SARS-CoV-2

○Yasumasa Iwatani^1,2 (1. NMC Nagoya Med. Ctr., 2. Nagoya Univ. Grad. School of Med.)

まとめ：三隅将吾（熊大院薬グローバル天然物科学研究セ） (3:10 PM - 3:15 PM)